PMC:7253482 / 210-333 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-PD-CLO

    {"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":76,"end":83},"obj":"http://purl.obolibrary.org/obo/CLO_0009985"}],"text":"hogens with high fatality rates and pandemic potential. Vaccine development focuses on the principal target of the neutrali"}

    LitCovid-sample-Enju

    {"project":"LitCovid-sample-Enju","denotations":[{"id":"T31","span":{"begin":7,"end":11},"obj":"IN"},{"id":"T32","span":{"begin":12,"end":16},"obj":"JJ"},{"id":"T33","span":{"begin":17,"end":25},"obj":"NN"},{"id":"T34","span":{"begin":26,"end":31},"obj":"NNS"},{"id":"T35","span":{"begin":32,"end":35},"obj":"CC"},{"id":"T36","span":{"begin":36,"end":44},"obj":"JJ"},{"id":"T37","span":{"begin":45,"end":54},"obj":"NN"},{"id":"T38","span":{"begin":56,"end":63},"obj":"NN"},{"id":"T39","span":{"begin":64,"end":75},"obj":"NN"},{"id":"T40","span":{"begin":76,"end":83},"obj":"VBZ"},{"id":"T41","span":{"begin":84,"end":86},"obj":"IN"},{"id":"T42","span":{"begin":87,"end":90},"obj":"DT"},{"id":"T43","span":{"begin":91,"end":100},"obj":"JJ"},{"id":"T44","span":{"begin":101,"end":107},"obj":"NN"},{"id":"T45","span":{"begin":108,"end":110},"obj":"IN"},{"id":"T46","span":{"begin":111,"end":114},"obj":"DT"}],"relations":[{"id":"R29","pred":"arg2Of","subj":"T35","obj":"T31"},{"id":"R30","pred":"arg1Of","subj":"T34","obj":"T32"},{"id":"R31","pred":"arg1Of","subj":"T34","obj":"T33"},{"id":"R32","pred":"arg1Of","subj":"T34","obj":"T35"},{"id":"R33","pred":"arg2Of","subj":"T37","obj":"T35"},{"id":"R34","pred":"arg1Of","subj":"T37","obj":"T36"},{"id":"R35","pred":"arg1Of","subj":"T39","obj":"T38"},{"id":"R36","pred":"arg1Of","subj":"T39","obj":"T40"},{"id":"R37","pred":"arg1Of","subj":"T40","obj":"T41"},{"id":"R38","pred":"arg2Of","subj":"T44","obj":"T41"},{"id":"R39","pred":"arg1Of","subj":"T44","obj":"T42"},{"id":"R40","pred":"arg1Of","subj":"T44","obj":"T43"},{"id":"R41","pred":"arg1Of","subj":"T44","obj":"T45"}],"text":"hogens with high fatality rates and pandemic potential. Vaccine development focuses on the principal target of the neutrali"}